Hims & Hers Health (NYSE:HIMS) Rating Increased to Buy at Needham & Company LLC

Needham & Company LLC upgraded shares of Hims & Hers Health (NYSE:HIMS) from a hold rating to a buy rating in a report issued on Monday, MarketBeat Ratings reports. They currently have $30.00 price target on the stock.

Several other research analysts have also issued reports on HIMS. Citigroup lowered their price target on shares of Hims & Hers Health from $16.50 to $13.25 and set a “sell” rating for the company in a report on Tuesday, February 24th. Barclays reduced their price objective on shares of Hims & Hers Health from $48.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 24th. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft set a $31.00 target price on shares of Hims & Hers Health and gave the company a “hold” rating in a report on Tuesday, February 10th. Finally, Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $29.77.

Hims & Hers Health Trading Up 40.5%

Shares of Hims & Hers Health stock opened at $22.12 on Monday. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a market capitalization of $5.04 billion, a price-to-earnings ratio of 43.37, a PEG ratio of 3.01 and a beta of 2.56. The firm’s 50-day moving average price is $24.51 and its two-hundred day moving average price is $37.89.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.11 EPS. On average, analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has authorized a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to buy up to 3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total value of $824,774.80. Following the completion of the sale, the chief financial officer directly owned 94,333 shares of the company’s stock, valued at approximately $3,369,574.76. The trade was a 19.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Chi sold 13,750 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the transaction, the chief operating officer owned 305,161 shares in the company, valued at $11,202,460.31. This represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 80,463 shares of company stock worth $2,846,696 over the last ninety days. 17.71% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Large investors have recently made changes to their positions in the company. Quent Capital LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth approximately $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health during the third quarter valued at approximately $28,000. Virtus Advisers LLC bought a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $26,000. Hilltop National Bank acquired a new position in shares of Hims & Hers Health during the third quarter worth approximately $35,000. Finally, Skandinaviska Enskilda Banken AB publ raised its position in shares of Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after purchasing an additional 600 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk ends lawsuit and agrees to distribute Wegovy/Ozempic via Hims — removes a recent existential legal threat and opens direct access to high‑margin, in‑demand GLP‑1 drugs on Hims’ platform, which could materially lift revenues and gross margins if commercial terms are solid. Read More.
• Positive Sentiment: Management/legal risk perceived as lower after the truce and public statements from Novo; media and analyst attention is framing this as a strategic pivot into branded GLP‑1 distribution. Read More.
• Positive Sentiment: Needham upgraded HIMS to Buy with a $30 price target, signaling some sell‑side support for upside from the deal and helping momentum. Read More.
• Neutral Sentiment: Extremely high short interest (reports cite ~81M shares short; a large % of the float) has made HIMS susceptible to a short squeeze — this can extend rallies quickly, but it’s driven by positioning rather than fundamentals. Read More.
• Neutral Sentiment: Heavy media coverage and volume are creating elevated short‑term volatility; further price moves will depend on the deal’s commercial details (pricing, exclusivity, timing) that aren’t fully public. Read More.
• Negative Sentiment: Analysts and commentators warn the rally may be unsustainable if the move is driven primarily by squeeze dynamics rather than durable fundamentals; sharp reversals are possible once positioning unwinds. Read More.
• Negative Sentiment: A securities‑litigation firm, Kahn Swick & Foti, has initiated an investigation into Hims’ officers and directors related to the prior Novo dispute — an active probe could prolong legal/PR risk even after the settlement. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.